Analysis of the clinical diagnosis and treatment of uveitis

Wang, Lina; Guo, Zaiyu; Zheng, Yan; Li, Qingyu; Yuan, Xiaoyong; Hua, Xia

doi:10.21037/apm-21-3549

Cited by 8 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We conducted a descriptive study of the patients with NIU followed up in the multidisciplinary uveitis unit of our hospital. The results did not differ from those reported in other published series [ 25 , 26 , 27 , 28 ]. There was no significant difference in sex, the mean age at diagnosis was 42.8 years, and the most frequent cases were anterior (74.4%) as well as unilateral (76.1%) uveitis.…”

Section: Discussionsupporting

confidence: 53%

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Esteban-Ortega,

Steiner,

Andreu-Vázquez

et al. 2024

JCM

View full text Add to dashboard Cite

Background: The aim of this study was to describe the characteristics of patients with uveitis associated with an immunologic or idiopathic disease that requires immunosuppressive treatment and the response to such treatments in real clinical practice. Methods: An observational, descriptive, longitudinal, and retrospective study of a cohort of patients diagnosed with noninfectious uveitis was performed. To assess the response to treatment, we evaluated the change in visual acuity, vitritis, and the presence of macular edema. Results: We included 356 patients. Overall, 12% required treatment with systemic corticosteroids, and 66 patients (18.5%) required immunosuppressive/biological treatment, with methotrexate being the most used (55%). Immunosuppressive drugs were used in 59 cases (in 56 patients, as the first choice of treatment and for 3 patients as the second choice after treatment with biologics). Treatment with biologics was the first choice in 10 patients out of 66 (15%), and 34 (48%) required them at some time during the disease, with adalimumab being the most commonly used. Thirty-five patients (53%) needed to switch drugs due to a lack of response to the first one. There were no differences between different drugs in the resolution of vitritis and improvement in vision. Conclusions: The use of systemic corticosteroids and immunosuppressive/biologics was necessary for a high number of patients with noninfectious uveitis. In our series, tocilizumab was significantly more effective in the resolution of macular edema.

show abstract

Section: Discussionsupporting

confidence: 53%

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Esteban-Ortega,

Steiner,

Andreu-Vázquez

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…We conducted a descriptive study of the patients with NIU followed up in the multidisciplinary uveitis unit of our hospital. The results did not differ from those reported in other published series [25][26][27][28]. There was no significant difference in sex, the mean age at diagnosis was 42.8 years, and the most frequent cases were anterior (74.4%) as well as unilateral (76.1%) uveitis.…”

Section: Discussionsupporting

confidence: 46%

Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

Esteban-Ortega,

Steiner,

Andreu-Vázquez

et al. 2024

Preprint

View full text Add to dashboard Cite

To describe the characteristics of patients with uveitis associated with an immunologic or idio-pathic disease that requires immunosuppressive treatment and the response to such treatments in real clinical practice. Observational, descriptive, longitudinal, and retrospective study of a cohort of patients diagnosed with idiopathic uveitis or autoimmune disease-related uveitis. To assess the response to treatment we have evaluated the change in visual acuity and vitritis and the presence of macular edema. We included 356 patients. Twelve percent required treatment with systemic corticosteroids and 66 patients (18.5%) immunosuppressive/biological treatment, with metho-trexate being the most used (55%). Immunosuppressive drugs were used in 59 cases the least re-sponsive being mycophenolate mofetil. Ten patients of the 66 (15%) started treatment with bio-logics. Thirty-five patients (53%) needed to switch drugs due to a lack of response to the first one. There were no differences between different drugs in the resolution of vitritis and improvement of vision. The disappearance of macular edema was achieved in all patients treated with tocilizumab. The use of systemic corticosteroids and Immunosuppressive/biologics was necessary for a high number of patients with non-infectious uveitis. In our series tocilizumab was significantly more effective in the resolution of macular edema.

show abstract

“…Uveitis is a common form of eye inflammation. Due to the complications, such as neovascularization and secondary intraocular pressure, uveitis is considered a major cause of eye damage [ 65 ]. Thuy et al found that MDS could efficiently detect abundant pathogens in the intraocular fluid of patients with uveitis.…”

Section: Applications Of Hts Technology In Ocular Diseasesmentioning

confidence: 99%

Application Progress of High-Throughput Sequencing in Ocular Diseases

Zhang²,

Cao³

et al. 2022

JCM

View full text Add to dashboard Cite

Ocular diseases affect multiple eye parts and can be caused by pathogenic infections, complications of systemic diseases, genetics, environment, and old age. Understanding the etiology and pathogenesis of eye diseases and improving their diagnosis and treatment are critical for preventing any adverse consequences of these diseases. Recently, the advancement of high-throughput sequencing (HTS) technology has paved wide prospects for identifying the pathogenesis, signaling pathways, and biomarkers involved in eye diseases. Due to the advantages of HTS in nucleic acid sequence recognition, HTS has not only identified several normal ocular surface microorganisms but has also discovered many pathogenic bacteria, fungi, parasites, and viruses associated with eye diseases, including rare pathogens that were previously difficult to identify. At present, HTS can directly sequence RNA, which will promote research on the occurrence, development, and underlying mechanism of eye diseases. Although HTS has certain limitations, including low effectiveness, contamination, and high cost, it is still superior to traditional diagnostic methods for its efficient and comprehensive diagnosis of ocular diseases. This review summarizes the progress of the application of HTS in ocular diseases, intending to explore the pathogenesis of eye diseases and improve their diagnosis.

show abstract

Analysis of the clinical diagnosis and treatment of uveitis

Cited by 8 publications

References 26 publications

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

Application Progress of High-Throughput Sequencing in Ocular Diseases

Contact Info

Product

Resources

About